[en] BACKGROUND AND OBJECTIVE: Early recognition of the ineffectiveness of chemotherapy could result in lower cumulative drug toxicity and tumor burden at the start of salvage therapy, which might improve clinical outcome. Therefore, we studied the value of (18)F-FDG PET for early evaluation of response in patients with non-Hodgkin's lymphoma (NHL). DESIGN AND METHODS: We studied 28 patients by (18)F-FDG PET after a median of 3 cycles of polychemotherapy. The presence or absence of abnormal (18)F-FDG uptake was correlated to clinical outcome (median follow-up: 17.5 months, range 4-47 months). RESULTS: Five of 28 patients still had increased (18)F-FDG uptake in one or more sites previously shown to be involved by lymphoma at baseline evaluation. Only one of these five patients entered complete remission (CR), whereas among the 23 patients with negative (18)F-FDG PET studies, two died of toxicity during chemotherapy and all the others entered clinical CR (p<0.00001). All five patients with and 7/21 patients without residual abnormal (18)F-FDG uptake relapsed or reprogressed (positive predictive value for relapse: 100%, negative predictive value: 67%). By Kaplan-Meier analysis, progression-free survival (PFS) at 1 and 2 years was respectively 20+/-18% and 0% for (18)F-FDG PET positive patients and 81+/-9% and 62+/-12% for (18)F-FDG PET negative patients (p=0.0001). Overall survival (OS) at 1 and 2 years was respectively 20+/-18% and 0% for (18)F-FDG PET positive and 87+/-7% and 68+/-11% for (18)F-FDG PET negative patients (p<0.0001). INTERPRETATION AND CONCLUSIONS: Persistent tumoral (18)F-FDG uptake after a few cycles of polychemotherapy is predictive of CR, PFS and OS in NHL. Further studies are warranted to determine whether (18)F-FDG PET has a predictive value independent from conventional prognostic factors. However, the sensitivity of qualitative (18)F-FDG PET imaging in identifying patients with a poor outcome was insufficient. Earlier evaluation after only one cycle of chemotherapy and quantitative analysis might increase the sensitivity of 18F-FDG PET is predicting treatment failure.
Disciplines :
Hematology
Author, co-author :
Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Fassotte, Marie-France ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Najjar, F.
Paulus, P.
Rigo, Pierre ; Université de Liège - ULiège > Département des sciences de la motricité > Pathologie générale et médecine nucléaire
Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
Armitage JO, Weisenburger DD, Hutchins M, et al. Chemotherapy for diffuse large-cell lymphoma - rapidly responding patients have more durable remissions. J Clin Oncol 1986; 4:160-4.
Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988; 6:931-3.
Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94:429-33.
Warburg O. On the origin of cancer cell. Science 1956; 123:309-14.
Callagher BM, Fowler JS, Gutterson NI, Mac Gregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of (F-18)-2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978; 19:1154-61.
Römer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91:4464-71.
Rahmouni A, Tempany C, Jones R, Mann R, Yang A, Zerhouni E. Lymphoma: monitoring tumor size and signal intensity with MRI imaging. Radiology 1993; 188:445-51.
Kaplan WD, Jochelson MS, Herman TS, et al. Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol 1990; 8:1966-70.
Janicek M, Kaplan W, Neuberg, Canellos GP, Shulman LN, Shipp MA. Early restating gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997; 15:1631-7.
Fayad L, Podoloff D, Rodriguez J, et al. Gallium (67Ga) scan result after second course of chemotherapy correlates with clinical outcome in aggressive poor prognosis non-Hodgkin's lymphomas (APPNHL) treated with alternating triple therapy regiment (ATT) [abstract]. Blood 1997; 90(Suppl):189a.
Ben Haim S, Bar-Shalom R, Frenkel A, Haim N, Israel O, Front D. Prediction of response in lymphoma patients by Ga-67 scintigraphy after one course of chemotherapy [abstract]. J Nucl Med 1996; 37(Sup-pl):139-40.
Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190:111-6.
Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body. 2-deoxy-2-[F-18] fluoro-D-glucose (FDG) PET In nodal staging. Radiology 1997; 203:795-800.
Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998; 206:475-81.
Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998; 91:3340-6.
Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose - positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998; 16:603-9.
Hoekstra OS, Ossenkoppele GJ, Golding R, et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 1993; 34:1706-10.
Dimitrakopoulou-Strauss A, Strauss LS, Goldschmidt H, Lorenz WJ, Maier-Borst W, Van Kaick G. Evaluation of tumor metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995; 22:434-42.
Zinzani PL, Magagnoli M, Chierichetti F, et al.The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999; 10:1181-4.
Jerusalem G, Warland V, Najjar F, et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999; 20:13-20.
Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36:1836-9.